Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 67.86 Million PLN | 684.11% |
| 2022 | -11.61 Million PLN | -48.79% |
| 2021 | -7.8 Million PLN | -168.17% |
| 2020 | 11.45 Million PLN | 28.5% |
| 2019 | 8.91 Million PLN | -29.4% |
| 2018 | 12.62 Million PLN | 9.1% |
| 2017 | 11.57 Million PLN | -81.52% |
| 2016 | 62.62 Million PLN | 50.63% |
| 2015 | 41.57 Million PLN | 80.83% |
| 2014 | 22.99 Million PLN | 101.12% |
| 2013 | 11.43 Million PLN | 308.29% |
| 2012 | 2.8 Million PLN | -74.62% |
| 2011 | 11.03 Million PLN | -48.58% |
| 2010 | 21.45 Million PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 64.8 Million PLN | -4.52% |
| 2024 Q2 | 81.89 Million PLN | 26.37% |
| 2023 Q2 | 11.29 Million PLN | 219.29% |
| 2023 Q4 | 67.86 Million PLN | 38.18% |
| 2023 FY | 67.86 Million PLN | 684.11% |
| 2023 Q3 | 49.11 Million PLN | 334.89% |
| 2023 Q1 | -9.46 Million PLN | 18.51% |
| 2022 Q3 | 6.68 Million PLN | 188.69% |
| 2022 FY | -11.61 Million PLN | -48.79% |
| 2022 Q2 | -7.53 Million PLN | 48.54% |
| 2022 Q4 | -11.61 Million PLN | -273.83% |
| 2022 Q1 | -14.64 Million PLN | -87.51% |
| 2021 Q3 | -1.82 Million PLN | 0.0% |
| 2021 Q4 | -7.8 Million PLN | -326.95% |
| 2021 FY | -7.8 Million PLN | -168.17% |
| 2021 Q1 | 14.78 Million PLN | 29.06% |
| 2020 Q2 | 13.18 Million PLN | 46.29% |
| 2020 Q4 | 11.45 Million PLN | -9.54% |
| 2020 FY | 11.45 Million PLN | 28.5% |
| 2020 Q3 | 12.66 Million PLN | -3.93% |
| 2020 Q1 | 9.01 Million PLN | 1.08% |
| 2019 Q3 | 8.28 Million PLN | -29.18% |
| 2019 Q4 | 8.91 Million PLN | 7.6% |
| 2019 Q2 | 11.69 Million PLN | 11.16% |
| 2019 Q1 | 10.52 Million PLN | -16.66% |
| 2019 FY | 8.91 Million PLN | -29.4% |
| 2018 Q3 | 12.62 Million PLN | 11.94% |
| 2018 Q1 | 10.66 Million PLN | -7.84% |
| 2018 Q4 | 12.62 Million PLN | 0.05% |
| 2018 FY | 12.62 Million PLN | 9.1% |
| 2018 Q2 | 11.27 Million PLN | 5.7% |
| 2017 Q4 | 11.57 Million PLN | -35.08% |
| 2017 FY | 11.57 Million PLN | -81.52% |
| 2017 Q2 | 20.63 Million PLN | -4.72% |
| 2017 Q3 | 17.83 Million PLN | -13.58% |
| 2017 Q1 | 21.65 Million PLN | -65.42% |
| 2016 Q4 | 62.62 Million PLN | 34322.95% |
| 2016 FY | 62.62 Million PLN | 50.63% |
| 2016 Q2 | -425 Thousand PLN | 53.09% |
| 2016 Q3 | -183 Thousand PLN | 56.94% |
| 2016 Q1 | -906 Thousand PLN | -102.18% |
| 2015 Q4 | 41.57 Million PLN | 728.63% |
| 2015 FY | 41.57 Million PLN | 80.83% |
| 2015 Q3 | -6.61 Million PLN | 77.96% |
| 2015 Q2 | -30 Million PLN | -104.87% |
| 2015 Q1 | -14.64 Million PLN | -163.71% |
| 2014 FY | 22.99 Million PLN | 101.12% |
| 2014 Q1 | 13.7 Million PLN | 19.89% |
| 2014 Q2 | 5.8 Million PLN | -57.65% |
| 2014 Q4 | 22.99 Million PLN | 854.26% |
| 2014 Q3 | -3.04 Million PLN | -152.51% |
| 2013 Q3 | 5.37 Million PLN | 4.01% |
| 2013 Q4 | 11.43 Million PLN | 112.59% |
| 2013 Q2 | 5.17 Million PLN | 16.5% |
| 2013 Q1 | 4.43 Million PLN | 58.49% |
| 2013 FY | 11.43 Million PLN | 308.29% |
| 2012 Q4 | 2.8 Million PLN | 0.0% |
| 2012 FY | 2.8 Million PLN | -74.62% |
| 2011 FY | 11.03 Million PLN | -48.58% |
| 2010 FY | 21.45 Million PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | 842.926% |
| BIOTON S.A. | 64.81 Million PLN | -4.718% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 194.358% |
| Mabion S.A. | -11.98 Million PLN | 666.086% |
| Molecure S.A. | -56.84 Million PLN | 219.383% |
| NanoGroup S.A. | -537.61 Thousand PLN | 12723.974% |
| Pharmena S.A. | -22.05 Million PLN | 407.708% |
| Poltreg S.A. | -57.75 Million PLN | 217.506% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | -627.261% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 218.998% |
| Urteste S.A. | -512 Thousand PLN | 13355.469% |